Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance

NCT01879241 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT01879241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01879241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2013
Completion date
August 31, 2016
Enrollment
252 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis